A Randomized Phase 2 Study to Evaluate Safety and Efficacy of the Combination of SHR-1210 With Capecitabine + Oxaliplatin or Apatinib as First-line Treatment in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Phase of Trial: Phase II
Latest Information Update: 04 Jun 2019
Price : $35 *
At a glance
- Drugs Camrelizumab (Primary) ; Capecitabine; Oxaliplatin; Rivoceranib
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 04 Jun 2019 Results (data cut off: 20 Jan 2019; n=43) assessing safety and efficay published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019).
- 15 May 2018 Status changed from not yet recruiting to recruiting.
- 22 Mar 2018 New trial record
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History